mic_none

Sun Pharma Source: en.wikipedia.org/wiki/Sun_Pharma

Sun Pharmaceutical Industries Limited
Company typePublic
ISININE044A01036
IndustryPharmaceuticals
Founded1983; 42 years ago (1983)
FounderDilip Shanghvi
Headquarters
Mumbai
,
India
Area served
Worldwide
Key people
Dilip Shanghvi (MD)
Products
RevenueIncrease ₹52,578 crore (US$6.2 billion) (2025)
Increase ₹15,271 crore (US$1.8 billion) (2025)
Increase ₹11,984 crore (US$1.4 billion) (2025)
Total assetsIncrease ₹92,100 crore (US$11 billion) (2025)
Total equityIncrease ₹72,485 crore (US$8.6 billion) (2025)
OwnerDilip Shanghvi family (54.48%)
Number of employees
41,000+ (2023)
Websitesunpharma.com
Footnotes / references
Financials as of 31 March 2025.[1][2]

Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries.[3] It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.[4][5]

Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover.[6] Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe.[7] The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.[4] Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin.[8]

History

[edit]

Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Calcutta, West Bengal with five psychiatry products and a two-person marketing team.[9][10][11]

Sun Pharma was listed on the stock exchange in 1994 in an issue that was oversubscribed 55 times. The founding family continues to hold a majority stake in the company.[4]

In 1996, Sun purchased a bulk drug manufacturing plant at Ahmednagar from Knoll Pharmaceuticals. Other notable acquisitions include plants of Gujarat Lyka Organics (1996), MJ Pharma (1996), and Tamil Nadu Dadha Pharmaceuticals Limited (1997). Also in 1997, Sun Pharma initiated their first foray into the international market with the acquisition of Caraco Pharmaceuticals based in Detroit.[12]

In 1998, Sun acquired a number of respiratory brands from Natco Pharma.[13] It acquired Melmet Labs (1999), Pradeep Drug Company (2000),[14] Phlox Pharma (2004), a formulation plant in the US and Hungary from Valeant Pharma and Able Labs (2005), and Chattem Chemicals (2008).[12]

In 2010, the company acquired a controlling stake in Taro Pharmaceuticals, amongst the largest generic dermatology companies in the US, with operations across Canada and Israel.[15]

In 2012, Sun announced acquisitions of two US companies: DUSA Pharmaceuticals, a dermatology device company;[16] and generics business of URL Pharma.[17]

In 2014, Sun Pharma entered into a licensing agreement with Merck & Co. Inc. to acquire rights for Tildrakizumab (MK- 3222) for treatment of chronic plaque psoriasis.[18]

To access sterile injectable capacity in the US, it acquired Pharmalucence in the US in the same year.[19]

On 6 April 2014, Sun Pharma announced the acquisition of Ranbaxy Laboratories in a US$4 billion transaction to create the world's fifth-largest specialty generic pharmaceutical company by sales.[20] In December 2014, the Competition Commission of India approved Sun Pharma's $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to prevent adverse impact on market competition.[21]

In March 2015, Sun Pharma announced it had agreed to buy GlaxoSmithKline's opiates business in Australia.[22]

In 2016, Sun Pharma acquired 14 prescription brands from Novartis in Japan to enter the Japanese market.[23] It also acquired Ocular Technologies to strengthen its branded ophthalmic portfolio[24] and Biosintez to enhance its presence in the Russian market.[25]

Sun Pharma launched its first branded ophthalmic product in the US, BromSite in 2016.[26] In 2017, the company launched its specialty product Odomzo[27] and then in 2018 another specialty product Ilumya (tildrakizumab-asmn) was launched to treat moderate-to-severe plaque psoriasis.[28]

In 2019, Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence.[29] The company entered the Greater China market by partnering with China Medical System Holdings[30] as well as launched a speciality product, Cequa, in the United States for the treatment of dry eyes.[31]

In 2023, Sun Pharma acquired a late-stage American biotechnology company Concert Pharmaceuticals,[32] and a 60% stake in animal healthcare company Vivaldis Animal Health and Foods.[33] 

In September 2023, Sun Pharma went into a licensing agreement with Pharmazz Inc.[34]

In January 2024, Sun Pharma entered into a definitive merger with Taro Pharmaceuticals to acquire the remaining stake in Taro Pharma for $347.73 million.[35]

In March 2025, it was announced Sun Pharma had acquired the Waltham, Massachusetts headquartered immunotherapy and targeted oncology treament company, Checkpoint Therapeutics for $355 million.[36][37]

SPARC

[edit]

In 2007, Sun Pharma demerged its innovative R&D arm, and listed it separately on the stock market as the Sun Pharma Advanced Research Company Ltd. (NSE: SPARC, BSE: 532872). In 2013, SPARC declared revenue of ₹873 million.[38] SPARC focuses on new chemical entities (NCE) research and new drug delivery systems and offers an annual update[39] of its pipeline (NDDS).[40]

References

[edit]
  1. ^ "Sun Pharma reports Q4 and full year results for FY25" (PDF). Sun Pharma. Retrieved 24 May 2025.
  2. ^ "Statement of Audited Consolidated Financial Results for the Quarter and Year ended March 31, 2025" (PDF). Sun Pharma. Retrieved 24 May 2025.
  3. ^ Banerjee, Avishek. "Sun Pharma: Global Is Local". BW Businessworld. Archived from the original on 26 July 2022. Retrieved 13 November 2022.
  4. ^ a b c "Sun Pharmaceuticals Industries Ltd". Business Standard India. Archived from the original on 9 August 2022. Retrieved 13 November 2022.
  5. ^ "Sun Pharma Industries". Forbes. Archived from the original on 23 September 2022. Retrieved 13 November 2022.
  6. ^ "US business remains Sun Pharma's weak spot". www.fortuneindia.com. 10 November 2017. Retrieved 6 August 2021.
  7. ^ "Creating Lasting Value Investor Presentation - February 2014" (PDF). Archived from the original (PDF) on 13 April 2014. Retrieved 10 April 2014.
  8. ^ "Sun Pharmaceutical Industries Ltd: Profile, Pharma Products, History...IBEF". India Brand Equity Foundation. Archived from the original on 24 May 2022. Retrieved 13 November 2022.
  9. ^ "Milestones & Recognitions | Sun Pharmaceutical Industries Limited". Sun Pharmaceutical Industries Ltd. Retrieved 6 August 2021.
  10. ^ "Strategic solutions", Hospitality Marketing, Routledge, pp. 210–219, 11 January 2013, doi:10.4324/9780080938486-27, ISBN 978-0-08-093848-6, retrieved 6 August 2021
  11. ^ Katja S, Ziegler (April 2019), "AWACS I (Ger)", Max Planck Encyclopedia of Comparative Constitutional Law, Oxford University Press, doi:10.1093/law-mpeccol/e542.013.542, retrieved 6 August 2021
  12. ^ a b Unnikrishnan, C.H. "Sun acquisitions on hold, will resume". Mint. Retrieved 24 May 2025.
  13. ^ "Sun Pharma Acquires Bevy Of Brands From Natco". Business Standard. 2 November 1998. Retrieved 24 May 2025.
  14. ^ "Sun Pharma announces 1:500 share swap for Pradeep Drugs". www.domain-b.com. 27 February 2001. Retrieved 24 May 2025.
  15. ^ "Sun Pharma buys controlling stake in Taro, shares up". The Economic Times. 22 September 2010. Retrieved 24 May 2025.
  16. ^ "Sun Pharma to buy U.S.-based Dusa for $230 mln". Reuters India. 8 November 2012. Retrieved 2 July 2015.
  17. ^ "Sun Pharma buys generic business of URL Pharma". Business Standard. Retrieved 24 May 2025.
  18. ^ "Sun Pharma, Merck & Co Inc enter into pact for Tildrakizumab". The Economic Times. Retrieved 6 August 2021.
  19. ^ Unnikrishnan, C. H. (16 July 2014). "Sun Pharma acquires US injectables firm Pharmalucence". mint. Retrieved 6 August 2021.
  20. ^ Reporter, B. S. (8 April 2014). "Sun Pharma buys Ranbaxy from Japan's Daiichi". Business Standard India. Retrieved 6 August 2021.
  21. ^ "CCI clears Sun Pharma-Ranbaxy deal". Reuters India. 9 December 2014. Retrieved 2 July 2015.
  22. ^ "UPDATE 1-India's Sun Pharma to buy Glaxo's opiates business in Australia". Reuters India. 3 March 2015. Retrieved 2 July 2015.
  23. ^ "Sun Pharma acquires Novartis brands in Japan for $293 million". @businessline. 29 March 2016. Retrieved 6 August 2021.
  24. ^ "Sun Pharma buys US-based Ocular Technologies for $ 40 million". Business Standard. Retrieved 24 May 2025.
  25. ^ "Sun Pharma to acquire 85 per cent stake in Russia's Biosintez". The Economic Times. 24 November 2016. Retrieved 24 May 2025.
  26. ^ "Sun Pharma Launches First Branded Ophthalmic Product in U.S." Ophthalmology Web. Retrieved 12 May 2022.
  27. ^ Trivedi, Isha (22 December 2016). "Sun Pharma to acquire Novartis's cancer drug Odomzo for $175 mn". mint. Retrieved 6 August 2021.
  28. ^ Medha (25 October 2018). "New drug launched for moderate-to-severe plaque psoriasis". speciality.medicaldialogues.in. Retrieved 6 August 2021.
  29. ^ "Sun Pharma to acquire Japan's Pola Pharma for $1 mn; to strengthen presence in dermatology segment". Firstpost. 27 November 2018. Retrieved 6 August 2021.
  30. ^ www.ETHealthworld.com. "Sun Pharma arm enters pact with China Medical System - ET HealthWorld". ETHealthworld.com. Retrieved 6 August 2021.
  31. ^ "Sun Pharma Launches Cequa for the Treatment of Dry Eye Disease in the US". Eyewire News. Retrieved 6 August 2021.
  32. ^ "Sun Pharma completes acquisition of Concert Pharmaceuticals". The Economic Times. 6 March 2023. Retrieved 24 May 2025.
  33. ^ "Sun Pharma to acquire 60% stake in animal healthcare company Vivaldis". cnbctv18.com. 24 March 2023. Retrieved 28 March 2023.
  34. ^ "Sun Pharma and Pharmazz Inc. enter into licensing agreement for introducing ischemic stroke drug in India". Financialexpress. 14 September 2023. Archived from the original on 3 May 2024. Retrieved 3 May 2024.
  35. ^ Das, Sohini (24 June 2024). "Sun Pharma completes Taro merger, acquires all outstanding shares". Business Standard. Retrieved 24 May 2025.
  36. ^ "Sun Pharma Agrees to Acquire Checkpoint Therapeutics". PharmTech. 12 March 2025. Retrieved 12 March 2025.
  37. ^ "Sun Pharma Acquires Checkpoint Therapeutics for $355 Million". PharmExec. 10 March 2025. Retrieved 12 March 2025.
  38. ^ "Sun Pharma Advanced Research Company Profit & Loss account, Sun Pharma Advanced Research Company Financial Statement & Accounts". Moneycontrol.com. Archived from the original on 3 July 2015. Retrieved 2 July 2015.
  39. ^ "Investor Update on R&D Pipeline" (PDF). Archived from the original (PDF) on 13 April 2014. Retrieved 12 May 2022.
  40. ^ "SUN PHARMA ADVANCED RESEARCH COMPANY". Sunpharma.in. Archived from the original on 2 February 2018. Retrieved 2 July 2015.
[edit]